Advanced medicines, mapped by therapy area.

A Trop-2 targeted antibody-drug conjugate for adults with triple-negative breast cancer who've already had two or more prior treatments.

Targets HER2-negative, hormone receptor-positive breast cancer that has progressed after endocrine therapy and chemotherapy.

An oral kinase inhibitor for HR-positive, HER2-negative breast cancer carrying PIK3CA, AKT1 or PTEN alterations.

Kinase inhibitor for ROS1-positive lung cancer, plus NTRK fusion-positive solid tumors in adults and adolescents 12 and up.

A BRAF-targeted therapy given in combination for BRAF V600-mutated melanoma, colorectal cancer, or non-small cell lung cancer.

Blocks the mutated KRAS G12C protein that drives advanced or metastatic non-small cell lung cancer.

First-line antibody therapy for Claudin 18.2-positive, HER2-negative gastric and gastroesophageal junction cancer, given alongside chemotherapy.

A PDE4 inhibitor tablet developed to slow the progression of idiopathic pulmonary fibrosis in adults.

An oral kinase inhibitor for non-small cell lung cancers driven by EGFR exon 20 insertion mutations.

Targets non-squamous lung cancers carrying HER2 kinase domain activating mutations, after prior systemic therapy.

A DLL3-targeting T-cell engager for extensive-stage small cell lung cancer that has progressed after platinum chemotherapy.

An oral estrogen receptor degrader for ER-positive, HER2-negative, ESR1-mutated breast cancer after endocrine therapy.

Used together with palbociclib and fulvestrant to treat PIK3CA-mutated, hormone receptor-positive advanced breast cancer.

An oral estrogen receptor antagonist for ESR1-mutated, ER-positive advanced breast cancer after endocrine treatment.

A PARP inhibitor for HER2-negative advanced breast cancer with a known or suspected germline BRCA mutation.

An alkylating agent for metastatic small cell lung cancer that has progressed on platinum-based chemotherapy.

A KRAS G12C inhibitor for previously treated, advanced lung cancer and colorectal cancer.

Paired with amivantamab as a first-line treatment for lung cancer with EGFR exon 19 deletions or L858R mutations.

A bispecific antibody for NRG1 fusion-positive advanced lung cancer that has progressed after prior therapy.

A kinase inhibitor for RET fusion-positive lung cancer and RET-mutant or fusion-positive thyroid cancers.

An oral therapy for adults with ROS1-positive, advanced or metastatic non-small cell lung cancer.

A c-Met directed antibody-drug conjugate for advanced, non-squamous non-small cell lung cancer.

A PD-1 blocking antibody approved across non-small cell lung cancer, cutaneous squamous cell carcinoma and basal cell carcinoma.

A HIF-2α inhibitor for von Hippel-Lindau disease-associated tumors and advanced renal cell carcinoma.

A gamma secretase inhibitor for adults with progressing desmoid tumors who need systemic treatment.

Targets unresectable or metastatic melanoma that carries the BRAF V600E mutation.

A protein-degrader therapy for ESR1-mutated, ER-positive advanced breast cancer after endocrine treatment.

A kinase inhibitor for metastatic colorectal cancer after prior chemotherapy and targeted regimens.

Treats intrahepatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements, after prior therapy.

A kinase inhibitor for non-squamous lung cancer with HER2 kinase domain mutations after prior systemic therapy.

A glucocorticoid receptor antagonist combined with nab-paclitaxel for platinum-resistant ovarian, fallopian tube or peritoneal cancer.